| Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model H Jespersen, MF Lindberg, M Donia, EMV Söderberg, R Andersen, ... Nature communications 8 (1), 707, 2017 | 170 | 2017 |
| Molecular profiling of driver events in metastatic uveal melanoma J Karlsson, LM Nilsson, S Mitra, S Alsén, GV Shelke, VR Sah, ... Nature communications 11 (1), 1894, 2020 | 122 | 2020 |
| The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma L Ny, H Jespersen, J Karlsson, S Alsén, S Filges, C All-Eriksson, ... Nature communications 12 (1), 5155, 2021 | 103 | 2021 |
| HER2 CAR-T cells eradicate uveal melanoma and T-cell therapy–resistant human melanoma in IL2 transgenic NOD/SCID IL2 receptor knockout mice EMV Forsberg, MF Lindberg, H Jespersen, S Alsén, RO Bagge, M Donia, ... Cancer Research 79 (5), 899-904, 2019 | 99 | 2019 |
| Melanoma patient-derived xenografts accurately model the disease and develop fast enough to guide treatment decisions BO Einarsdottir, RO Bagge, J Bhadury, H Jespersen, J Mattsson, ... Oncotarget 5 (20), 9609, 2014 | 73 | 2014 |
| Lipids, curvature stress, and the action of lipid prodrugs: Free fatty acids and lysolipid enhancement of drug transport across liposomal membranes H Jespersen, JH Andersen, HJ Ditzel, OG Mouritsen Biochimie 94 (1), 2-10, 2012 | 54 | 2012 |
| Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study H Jespersen, R Olofsson Bagge, G Ullenhag, A Carneiro, H Helgadottir, ... BMC cancer 19, 1-7, 2019 | 50 | 2019 |
| A patient-derived xenograft pre-clinical trial reveals treatment responses and a resistance mechanism to karonudib in metastatic melanoma BO Einarsdottir, J Karlsson, EMV Söderberg, MF Lindberg, ... Cell Death & Disease 9 (8), 810, 2018 | 40 | 2018 |
| Supporting clinical decision making in advanced melanoma by preclinical testing in personalized immune-humanized xenograft mouse models L Ny, LY Rizzo, V Belgrano, J Karlsson, H Jespersen, L Carstam, ... Annals of Oncology 31 (2), 266-273, 2020 | 36 | 2020 |
| Real-world data on PD-1 inhibitor therapy in metastatic melanoma A Arheden, J Skalenius, S Bjursten, U Stierner, L Ny, M Levin, ... Acta Oncologica 58 (7), 962-966, 2019 | 31 | 2019 |
| Effect of free fatty acids and lysolipids on cellular uptake of doxorubicin in human breast cancer cell lines N Rasmussen, JH Andersen, H Jespersen, OG Mouritsen, HJ Ditzel Anti-cancer drugs 21 (7), 674-677, 2010 | 30 | 2010 |
| Checkpoint inhibitor-induced sarcoid reaction mimicking bone metastases H Jespersen, S Bjursten, L Ny, M Levin The Lancet Oncology 19 (6), e327, 2018 | 25 | 2018 |
| Epigenetic therapy to enhance therapeutic effects of PD-1 inhibition in therapy-resistant melanoma VR Sah, J Karlsson, H Jespersen, MF Lindberg, LM Nilsson, L Ny, ... Melanoma Research 32 (4), 241-248, 2022 | 15 | 2022 |
| Phase II multicenter open label study of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study) H Jespersen, RO Bagge, G Ullenhag, A Carneiro, H Helgadottir, ... Annals of Oncology 30, v907, 2019 | 12 | 2019 |
| Early rise in brain damage markers and high ICOS expression in CD4+ and CD8+ T cells during checkpoint inhibitor-induced encephalomyelitis S Bjursten, A Pandita, Z Zhao, C Fröjd, L Ny, C Jensen, T Ullerstam, ... Journal for Immunotherapy of Cancer 9 (7), 2021 | 11 | 2021 |
| Mutational signature and transcriptomic classification analyses as the decisive diagnostic tools for a cancer of unknown primary RO Bagge, A Demir, J Karlsson, B Alaei-Mahabadi, BO Einarsdottir, ... JCO precision oncology 2, 1-25, 2018 | 11 | 2018 |
| Surgery of metastatic melanoma after systemic therapy–the SUMMIST trial: study protocol for a randomized controlled trial CJ Holmberg, D Katsarelias, H Jespersen, A Carneiro, NO Elander, ... Acta Oncologica 60 (1), 52-55, 2021 | 6 | 2021 |
| Molecular profiling of driver events and tumor-infiltrating lymphocytes in metastatic uveal melanoma J Karlsson, LM Nilsson, EMV Forsberg, S Mitra, S Alsén, G Shelke, ... bioRxiv, 742023, 2019 | 3 | 2019 |
| Chemokine analysis in patients with metastatic uveal melanoma suggests a role for CCL21 signaling in combined epigenetic therapy and checkpoint immunotherapy VR Sah, H Jespersen, J Karlsson, LM Nilsson, M Bergqvist, I Johansson, ... Cancer Research Communications 3 (5), 884-895, 2023 | 1 | 2023 |
| Epigenetic therapy to enhance therapeutic effects of PD-1 inhibition in uveal melanoma VR Sah, H Jespersen, J Karlsson, MF Lindberg, LM Nilsson, L Ny, ... bioRxiv, 2021.02. 04.429575, 2021 | 1 | 2021 |
